Table 3 Results from the sensitivity analysis
Base case ICER | Dominant | Low value | High Value | ||
|---|---|---|---|---|---|
Parameter | Base case value | High value | ICER | Low value | ICER |
PFS: EVE plus EXE vs. BEV plus PACL (−50 %; +50 %) | 50 % | 1,384 € | 150 % | Dominant | |
PFS: BEV plus PACL (−50 %; +50 %) | 50 % | Dominant | 150 % | Dominant | |
PFS: EVE plus EXE vs. BEV plus CAPE (−50 %; +50 %) | 50 % | 26,091 € | 150 % | Dominant | |
PFS: BEV plus CAPE (−50 %; +50 %) | 50 % | Dominant | 150 % | Dominant | |
OS: EVE plus EXE vs. BEV plus PACL (−50 %; +50 %) | 50 % | €11,251 € | 150 % | Dominant | |
OS: BEV plus PACL (−50 %; +50 %) | 50 % | Dominant | 150 % | Dominant | |
OS: EVE plus EXE vs. BEV plus CAPE (−50 %; +50 %) | 50 % | 17,104 € | 150 % | Dominant | |
OS: BEV plus CAPE (−50 %; +50 %) | 50 % | Dominant | 150 % | 5,876 € | |
Fixed post-progression survival (6–48 months) | 12 | 6 | Dominant | 48 | Dominant |
Utility: pre-progression (0.36; 0.90) | 0.773 | 0.36 | Dominant | 0.90 | Dominant |
Utility: post-progression (0.2; 0.97) | 0.496 | 0.22 | Dominant | 0.97 | Dominant |
Pre-progression background costs (50 €; 150 €) | 95.16 € | 50.00 € | Dominant | 150 € | Dominant |
Post-progression background costs (500 €; 1500 €) | 1,057.41 € | 500.00 € | Dominant | 1,500 € | Dominant |
Adverse event costs: EVE plus EXE (38 €; 133 €) | 62 € | 37.89 € | Dominant | 133 € | Dominant |
Adverse event costs: BEV plus PACL (4.92 €; 34 €) | 5.14 € | 4.92 € | Dominant | 34 € | Dominant |
Adverse event costs: BEV plus CAPE (0.50 €; 34 €) | 1 € | 0.50 € | Dominant | 34 € | Dominant |
Adverse event disutilities: EVE plus EXE (0.011; 0.04) | −0.029 | −0.011 | Dominant | −0.04 | Dominant |
Adverse event disutilities: BEV plus PACL (0.005; 0.069) | 0.027 | −0.005 | Dominant | −0.069 | Dominant |
Adverse event disutilities: BEV plus CAPE (0.005; 0.069) | −0.0031 | −0.002 | Dominant | −0.069 | Dominant |
Adverse events: unknown disutility assumption (−0.01; −0.10) | −0.05 | −0.013 | Dominant | −0.100 | Dominant |
BOLERO II Central PFS included | Without | With | Dominant | ||
Fixed post-progression survival applied | Without | With | Dominant | ||
Dose intensity included | Without | With | Dominant | ||
Drug cost: EVE plus EXE vs. BEV plus PACL (2000 €; 5000 €) | 2,447.75 € | 2000 € | Dominant | 5,000 € | 324,159 € |
Drug cost: BEV plus PACL (2000 €; 5000 €) | 3,806.42 € | 2000 € | 151,243 € | 5,000 € | Dominant |
Drug cost: EVE plus EXE vs. BEV plus CAPE (2000 €; 5000 €) | 2,447.75 | 2000 € | Dominant | 5,000 € | 4,082,144 € |
Drug cost: BEV plus CAPE (2000 €; 5000 €) | 3,510.97€ | 2000 € | 3,539,497 € | 5,000 € | Dominant |
Extrapolation method (EVE plus EXE versus comparator) | |||||
Exponential, endpoint (PACL) | Dominant | ||||
Exponential, endpoint (CAPE) | Less effective | ||||
Gompertz (PACL) | Dominant | ||||
Gompertz (CAPE) | Less effective | ||||
Exponential, curve (PACL) | Dominant | ||||
Exponential, curve (CAPE) | Less effective | ||||
Log-logistic(PACL) | Dominant | ||||
Log-logistic (CAPE) | Dominant | ||||